Kymera Therapeutics, Inc. $KYMR Shares Newly Bought by Mirae Asset Global Investments Co. Ltd.

Mirae Asset Global Investments Co. Ltd. bought a new position in Kymera Therapeutics, Inc. (NASDAQ:KYMR) in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 4,599 shares of the company’s stock, valued at approximately $514,000.

Several other hedge funds and other institutional investors have also recently made changes to their positions in KYMR. China Universal Asset Management Co. Ltd. raised its holdings in Kymera Therapeutics by 20.8% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 15,812 shares of the company’s stock worth $1,747,000 after acquiring an additional 2,721 shares during the last quarter. Sterling Capital Management LLC increased its holdings in shares of Kymera Therapeutics by 378.6% in the 3rd quarter. Sterling Capital Management LLC now owns 1,919 shares of the company’s stock worth $215,000 after purchasing an additional 1,518 shares in the last quarter. Inspire Investing LLC bought a new stake in shares of Kymera Therapeutics in the 3rd quarter worth $482,000. Nisa Investment Advisors LLC increased its holdings in shares of Kymera Therapeutics by 45.9% in the 3rd quarter. Nisa Investment Advisors LLC now owns 2,073 shares of the company’s stock worth $232,000 after purchasing an additional 652 shares in the last quarter. Finally, Abel Hall LLC raised its stake in shares of Kymera Therapeutics by 4.0% in the third quarter. Abel Hall LLC now owns 4,870 shares of the company’s stock worth $544,000 after purchasing an additional 189 shares during the last quarter.

Insider Activity at Kymera Therapeutics

In other Kymera Therapeutics news, CEO Nello Mainolfi sold 30,000 shares of the stock in a transaction that occurred on Thursday, October 1st. The shares were sold at an average price of $113.80, for a total value of $3,414,000.00. Following the transaction, the chief executive officer directly owned 666,568 shares in the company, valued at approximately $75,855,438.40. This trade represents a 4.31% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Brian Adams sold 6,371 shares of Kymera Therapeutics stock in a transaction on Friday, September 4th. The stock was sold at an average price of $116.83, for a total transaction of $744,323.93. Following the transaction, the insider owned 50,254 shares in the company, valued at $5,871,174.82. This represents a 11.25% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 15.98% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently issued reports on KYMR. Wells Fargo & Company upped their price target on Kymera Therapeutics from $116.00 to $151.00 and gave the company an “overweight” rating in a report on Thursday, August 27th. Royal Bank Of Canada lifted their price objective on Kymera Therapeutics from $112.00 to $116.00 and gave the stock a “sector perform” rating in a report on Friday, October 30th. Stifel Nicolaus boosted their target price on Kymera Therapeutics from $132.00 to $152.00 and gave the stock a “buy” rating in a research report on Tuesday, September 22nd. Mizuho boosted their target price on Kymera Therapeutics from $120.00 to $140.00 and gave the stock an “outperform” rating in a research report on Thursday, July 16th. Finally, Morgan Stanley upped their target price on shares of Kymera Therapeutics from $135.00 to $146.00 and gave the company an “overweight” rating in a research note on Tuesday, October 27th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $139.16.

Kymera Therapeutics Stock Up 5.4%

Kymera Therapeutics stock opened at $138.86 on Tuesday. The business has a 50-day simple moving average of $116.09 and a two-hundred day simple moving average of $98.15. The company has a market cap of $11.85 billion, a P/E ratio of -38.36 and a beta of 2.04. Kymera Therapeutics, Inc. has a 52-week low of $58.87 and a 52-week high of $140.67.

Kymera Therapeutics (NASDAQ:KYMR) last issued its quarterly earnings data on Thursday, October 29th. The company reported ($1.32) earnings per share for the quarter, missing the consensus estimate of ($1.26) by ($0.06). The business had revenue of $1.35 million during the quarter, compared to the consensus estimate of $3.28 million. Kymera Therapeutics had a negative return on equity of 22.39% and a negative net margin of 285.33%. Kymera Therapeutics’s revenue for the quarter was up .0% on a year-over-year basis. During the same quarter last year, the company earned ($0.94) EPS. Research analysts anticipate that Kymera Therapeutics, Inc. will post -3.88 EPS for the current fiscal year.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical-stage biotechnology company developing medicines that selectively remove disease-causing proteins from cells. Its approach, known as targeted protein degradation, uses the body’s natural protein-disposal system and is designed to address targets that may be difficult to reach with conventional drugs.

The company’s research and development programs include small-molecule protein degraders for conditions involving immune and inflammatory pathways, as well as cancer.